Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).

被引：0
|
作者：
Garcia-Manero, Guillermo
Yang, Allen S.
Giles, Francis
Faderl, Stefan
Ravandi, Farhad
Cortes, Jorge
Newsome, Willie M.
Issa, Jean-Pierre
Patterson, Tracy-Ann
Dubay, Marja
Li, Zuomei
Kantarjian, Hagop
Martell, Robert E.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ So Calif, Norris Comprehens Canc Ctr, Div Hematol, Los Angeles, CA USA
[3] MethylGene Inc, Montreal, PQ, Canada
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1954
引用
收藏
页码：552A / 553A
页数：2
相关论文
共 50 条
  • [1] Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    Garcia-Manero, G.
    Yang, A. S.
    Klimek, V.
    Luger, S.
    Newsome, W. M.
    Berman, N.
    Patterson, T.
    Maroun, C.
    Li, Z.
    Ward, R.
    Martell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)
    DiPersio, John
    Stadtmauer, Edward A.
    Nademanee, Auaypom P.
    Stiff, Patrick
    Micallef, Ivana
    Angell, J.
    Bridger, G.
    Calandra, Gary
    BLOOD, 2007, 110 (11) : 137A - 137A
  • [3] Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors
    Hurwitz, H.
    Nelson, B.
    O'Dwyer, P. J.
    Chiorean, E. G.
    Gabrail, N.
    Li, Z.
    Laille, E.
    Drouin, M.
    Rothenberg, M. L.
    Chan, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS)
    Luger, Selina M.
    O'Connell, Casey Lee
    Klimek, Virginia
    Cooper, Maureen A.
    Besa, Emmanuel C.
    Rossetti, James M.
    Reid, Gregory K.
    Humphrey, Rachel
    Martell, Robert E.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors
    Hurwitz, Herbert I.
    Chan, Emily
    O'Dwyer, Peter
    Gabrail, Nashat
    Li, Zuomei
    Kalita, Ann
    Bourget, M. C. Trachy
    Tawashi, Manal
    Martell, R. E.
    Ward, R.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3477S - 3477S
  • [6] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [7] Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
    Garcia-Manero, Guillermo
    Assouline, Sarit
    Cortes, Jorge
    Estrov, Zeev
    Kantarjian, Hagop
    Yang, Hui
    Newsome, Willie M.
    Miller, Wilson H., Jr.
    Rousseau, Caroline
    Kalita, Ann
    Bonfils, Claire
    Dubay, Marja
    Patterson, Tracy-Ann
    Li, Zuomei
    Besterman, Jeffrey M.
    Reid, Gregory
    Laille, Eric
    Martell, Robert E.
    Minden, Mark
    BLOOD, 2008, 112 (04) : 981 - 989
  • [8] Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors.
    Carducci, M.
    Siu, L. L.
    Sullivan, R.
    Maclean, M.
    Kalita, A.
    Chen, E. X.
    Pili, R.
    Martell, R. E.
    Besterman, J.
    Reid, G. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 122S - 122S
  • [9] Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors.
    Siu, LL
    Carducci, M
    Pearce, L
    Maclean, M
    Sullivan, R
    Li, ZM
    Kalita, A
    Chen, EX
    Pili, R
    Longstreth, J
    Martell, RE
    Reid, GK
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9118S - 9118S
  • [10] Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, Anas
    Wedgwood, Amanda
    McLaughlin, Peter
    Andreadis, Charalambos
    Assouline, Sarit E.
    Li, Zuomei
    Martell, Robert E.
    Dubay, Marja
    Patterson, Tracy-Ann
    Ward, Michelle R.
    Crump, Michael
    BLOOD, 2007, 110 (11) : 758A - 758A
12345